Title: Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial
Authors: Burris, Howard A ×
Lebrun, Fabienne
Rugo, Hope S
Beck, J Thaddeus
Piccart, Martine
Neven, Patrick
Baselga, Jose
Petrakova, Katarina
Hortobagyi, Gabriel N
Komorowski, Anna
Chouinard, Edmond
Young, Robyn
Gnant, Michael
Pritchard, Kathleen I
Bennett, Lee
Ricci, Jean-Francois
Bauly, Hounayda
Taran, Tetiana
Sahmoud, Tarek
Noguchi, Shinzaburo #
Issue Date: 15-May-2013
Publisher: John Wiley & Sons
Series Title: Cancer vol:119 issue:10 pages:1908-15
Article number: 10.1002/cncr.28010
Abstract: The randomized, controlled BOLERO-2 (Breast Cancer Trials of Oral Everolimus) trial demonstrated significantly improved progression-free survival with the use of everolimus plus exemestane (EVE + EXE) versus placebo plus exemestane (PBO + EXE) in patients with advanced breast cancer who developed disease progression after treatment with nonsteroidal aromatase inhibitors. This analysis investigated the treatment effects on health-related quality of life (HRQOL).
ISSN: 0008-543X
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gynaecological Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science